IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab by Marisi, Giorgia et al.
© 2018 Marisi et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work 
you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Cancer Management and Research 2018:10 5659–5666
Cancer Management and Research Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
5659
O R i g i n a l  R e s e a R C h
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/CMAR.S181570
il-8 and thrombospondin-1 as prognostic 
markers in patients with metastatic colorectal 
cancer receiving bevacizumab
giorgia Marisi1  
emanuela scarpi2 
alessandro Passardi3  
Oriana nanni2  
Flavia Pagan2  
Martina Valgiusti3  
andrea Casadei gardini3  
luca Maria neri4  
giovanni luca Frassineti3  
Dino amadori3  
Paola Ulivi1
1Biosciences laboratory, istituto 
scientifico Romagnolo per lo 
studio e la Cura dei Tumori (iRsT) 
iRCCs, Meldola 47014, italy; 2Unit 
of Biostatistics and Clinical Trials, 
istituto scientifico Romagnolo 
per lo studio e la Cura dei Tumori 
(iRsT) iRCCs, Meldola 47014, italy; 
3Department of Medical Oncology, 
istituto scientifico Romagnolo 
per lo studio e la Cura dei Tumori 
(iRsT) iRCCs, Meldola 47014, italy; 
4Department of Morphology, surgery 
and experimental Medicine, University 
of Ferrara, Ferrara 44100, italy
Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment 
of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. 
We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.
Patients and methods: Serum samples collected at baseline and at the first clinical evalua-
tion were available for 58 patients enrolled in the randomized multicenter ITACa trial and who 
received CT+ B. Serum protein levels were determined using multiplex ELISA.
Results: Patients with baseline ≥145 pg/mL IL-8 showed shorter median progression-free 
survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, 
P<0.0001 and 8.7 vs 28.8 months, HR 7.68, P<0.001, respectively). Moreover, patients with 
baseline thrombospondin-1 levels ≥12,000 ng/mL had a better median OS than those with lower 
levels (34.5 vs 13.1 months, HR 0.43, P=0.007). Patients with a ≥20% reduction in IL-8 levels 
from baseline to first clinical evaluation showed a better progression-free survival and OS than 
the others (HR 0.41, P=0.005 and HR 0.43, P=0.007, respectively).
Conclusion: Baseline IL-8 and thrombospondin-1 levels and reduced IL-8 during B treatment 
could represent potential prognostic markers in metastatic colorectal cancer.
Keywords: serum biomarkers, targeted therapy, IL-8, angiogenesis, chemotherapy
Introduction
Over the last few years, the management of metastatic colorectal cancer (mCRC) has 
changed substantially thanks to the availability of two classes of biological drugs: anti-
angiogenic drugs, such as bevacizumab, aflibercet, and regorafenib, and anti-epidermal 
growth factor receptor inhibitors, such as cetuximab and panitumumab.1 Although 
RAS mutations have consistently been associated with reduced overall survival (OS), 
progression-free survival (PFS), and higher treatment failure rates among mCRC 
patients treated with anti-epidermal growth factor receptor antibodies,2 no genetic or 
molecular markers for anti-angiogenic drugs have been found as yet. The discovery 
of such markers to predict or monitor the efficacy of B would help to identify patients 
who are more likely to benefit from therapy.
Bevacizumab (B) is a humanized monoclonal antibody targeting vascular endo-
thelial growth factor (VEGF), a critical angiogenic factor involved in both physi-
ological and pathological conditions. Preclinical studies suggest that the alternation 
of proangiogenic factors may modulate sensitivity to anti-VEGF therapy and allow 
regrowth of tumor-associated vasculature.3 Previous studies assessed circulating 
levels of pro- and antiangiogenic factors at baseline and during therapy in relation to 
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the B response in different types of tumors, with conflicting 
results. Baseline plasma levels of the soluble VEGF recep-
tor 1 (sVEGFR-1), VEGF, placental-derived growth factor 
(PlGF), and IL-6 during treatment showed a significant cor-
relation with outcome in patients with locally advanced rectal 
carcinoma.4 Basic fibroblast growth factor, PlGF, hepatocyte 
growth factor (HGF), stromal cell-derived factor 1 (SDF-1), 
and monocyte-chemotactic protein 3 were shown to increase 
prior to disease progression in mCRC patients.5,6 sVEGFR-2, 
thrombospondin-1 (TSP-1),6 and VEGF-D7 were also higher 
in progressive disease in this patient setting.
In contrast, high baseline epidermal growth factor (EGF) 
and macrophage-derived chemokine (MDC) expression but 
low levels of IL-6, IL-8, and IL-10 were observed in mCRC 
patients responding to therapy.8 Furthermore, Wallyn dem-
onstrated that a significant decrease in the expression of a 
small proteoglycan, endocan was a good prognosis marker 
in patients with stage IIIB–IV non-small-cell lung cancer 
treated with B.9 In patients with ovarian cancer treated with 
B, high levels of angiopoietin-1 (Ang-1) and low levels of the 
angiopoietin receptor Tie2 were associated with better PFS.10 
In advanced renal cell carcinoma, serum Ang-2 and hypoxia-
inducible factor 1-alpha (HIF-1α) tumor levels were important 
markers of the efficacy of sunitinib, another antiangiogenic 
drug.11 However, none of these results has been consistently 
replicated across different studies and cancer types.12,13
In an attempt to overcome some of the limitations of 
earlier investigations, we simultaneously assessed a series 
of cytokines and angiogenic factors with a multiplex ELISA 
in mCRC patients treated with B. We measured the levels of 
22 angiogenesis-associated proteins (FGF-basic, HGF, sTIE-
2, sVEGFR-1, sVEGFR-2, Ang-2, EGF, IL-6, IL-8, PlGF, 
VEGF-A, VEGF-C, VEGF-D, PDGF-bb, Ang-1, SDF-1α, 
MDC, galectin-1, TSP1, endocan, eNOS, and HIF-1α) at 
baseline and during treatment to investigate whether changes 
in their levels might be correlated with therapeutic efficacy 
and disease outcome.
Patients and methods
Patient selection and treatment
This study included patients enrolled in the ITACa clinical 
trial (NCT01878422).14 Of the 376, we taken in consider-
ation 58 patients receiving first-line chemotherapy (CT) 
(FOLFOX4 or FOLFIRI) plus B for which peripheral blood 
samples were available. Additional details about the treat-
ment regimen and clinical outcomes for ITACa trial have 
previously been reported.14 Written informed consent was 
obtained from each patient regarding the use of serum for 
this correlative analysis. All patients underwent evaluation 
of RAS, BRAF, and microsatellite instability (MSI) status 
during their routine molecular diagnostic characterization.
Patients were evaluated for response according to 
RECIST criteria version 1.1. Tumor responses were assessed 
every 8 weeks by imaging tools such as computed tomog-
raphy. Responders included complete response and partial 
response. Nonresponders included stable disease and disease 
progression.
All subjects gave their informed consent for inclusion 
before they participated in the study. The study was conducted 
in accordance with the Declaration of Helsinki, and the 
protocol was approved by Local Ethics Committee (Ethics 
Committee Area Vasta Romagna and IRST).
Plasma collection, handling, and storage
Venous blood was drawn into EDTA vacutainer tubes and 
immediately processed for serum at baseline and at the first 
evaluation (about 2 months after the start of treatment). The 
tubes were centrifuged at 2,500× g for 15 minutes. The top 
layer of serum was aliquoted into 2 mL fresh tubes and stored 
at –80°C until use. Blood samples were available for analysis 
at baseline for 58 patients and at the first clinical evaluation 
for 55 patients (95%). All data were collected in accordance 
with good clinical practice guidelines.
Biomarker assessments and methodology
Levels of all serum proteins were determined using a Bio-
Plex 200 array reader based on Luminex X-Map Technology 
(Bio-Rad Laboratories Inc., Hercules, CA, USA). Angio-
genesis-associated protein concentrations were assessed in 
duplicate using a 5-plex ELISA assay of FGFb, HGF, sTie2s, 
VEGFR-1, and sVEGFR-2, an 8-plex assay of Ang-2, EGF, 
IL-6, IL-8, PlGF, VEGFA, VEGFC, and VEGFD, a 2-duplex 
assay of Ang-1 and PDGFbb and SDF-1α/CXCL12 and 
MDC/CCL22, and 5 singleplex ELISA assays of galectin-1, 
TSP-1, endocan, eNOS, and HIF-1α.
The protein concentrations (expressed as pg/mL or ng/
mL) were calculated through a standard curve using the 
software provided by the manufacturer (Bio-Plex Manager 
Software v.6.1).
The assays were performed blinded to the study endpoint 
by Bioclarma Research and Molecular Diagnostics (Turin, 
Italy).
statistical analyses
The primary aim of the ITACa study was PFS, while second-
ary endpoints were OS and objective response rate (ORR). 
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In the present work, we aimed to examine the association 
between 22 angiogenesis-associated proteins and PFS, OS, 
and ORR in the ITACa population and to investigate their 
variation during B treatment. The relationship between base-
line serum proteins and clinical characteristics was analyzed 
using a nonparametric ranking statistic (median test). Logistic 
regression models and their 95% CIs, adjusted for baseline 
characteristics (gender, age, RAS status, tumor localization, 
and CT regimen) were used to evaluate the association 
between serum protein baseline levels and ORR (complete 
response + partial response). Covariate selection was based 
on a list of probable prognostic factors from the ITACa 
study.14 PFS was calculated as the time elapsed between 
the date of randomization and the date of first observation 
of progressive disease or the date of last tumor evaluation 
or the date of death in the absence of disease progression. 
OS was calculated as the time elapsed between the date of 
randomization and the date of death from any cause or the 
date of last follow-up. PFS and OS were estimated using the 
Kaplan–Meier method and were compared with the logrank 
test. 95% CIs were calculated by nonparametric methods. 
The Cox regression model was used to estimate HRs and 
their 95% CIs, adjusting for baseline characteristics. Base-
line levels of serum proteins were dichotomized using the 
best cutoff determined by receiver-operating characteristic 
analysis at a median PFS. The median value of variation in 
the serum proteins from baseline to the first clinical evalua-
tion was chosen as the cutoff point (20%). We conducted a 
landmark analysis to reduce potential confounding by time 
on treatment by assessing the impact of change in serum 
proteins form baseline to the first tumor evaluation (about 
2 months after the start of treatment) on survival outcome. 
Patients who were still alive and had not been lost to follow-
up at the landmark time were divided into two categories on 
the basis of whether they had progressed or not by that time. 
PFS and OS after the landmark time were computed with 
Kaplan–Meier curves. All P-values were based on two-sided 
testing, and statistical analyses were carried out using SAS 
statistical software version 9.4 (SAS Institute, Cary, NC, 
USA). Adjustments for multiple comparisons were not made, 
given the exploratory nature of the study.
Results
Patient characteristics
The clinical pathological characteristics of patients are shown 
in Table 1. Median age was 65 (37–83) years. Median PFS 
and OS were 12.1 months (95% CI 9.2–14.7) and 25.2 months 
(95% CI 17.8–34.5), respectively. Median follow-up was 64 
months (range 2–79). A total of 31 (53%) patients were RAS 
mutated, while 7 (15%) were BRAF mutated. Twenty-eight 
patients had microsatellite stable tumors, one had a low MSI 
tumor and only four had high MSI disease.
serum proteins at baseline
We evaluated the correlation between the main clinical 
pathological characteristics of patients and median baseline 
biomarker levels, observing a higher median baseline FGF 
level in right-sided tumors than in left-sided ones (92.98 
pg/mL [range 38.55–199.07] and 60.84 pg/mL [range 
17.43–93.76], respectively) (P=0.002). No significant dif-
ferences were observed between median baseline biomarker 
Table 1 Patient characteristics (n=58)
Patient characteristics Total, N (%)
Median age, years (range) 65 (37–83)
Gender
Male 39 (67.2)
Female 19 (32.8)
Performance Status (ECOG)
0 51 (87.9)
1–2 7 (12.1)
Tumor localization
Rectum 17 (29.3)
Colon 41 (70.7)
Right-sided 25 (44.6)
left-sided 31 (55.4)
Unknown/missing 2
Stage at diagnosis
i–iii 14 (24.1)
iV 44 (75.9)
Grade
1+2 31 (62.0)
3 19 (38.0)
Unknown/missing 8
CT regimen
FOlFOX4 37 (63.8)
FOlFiRi 21 (36.2)
RAS status
Wild type 27 (46.6)
Mutated 31 (53.4)
BRAF status
Wild type 51 (87.9)
Mutated 7 (12.1)
MSI status
stable-low instability 29 (87.9)
high instability 4 (12.1)
Unknown/missing 25
Prior cancer therapy
surgery 44 (75.9)
Radiotherapy 5 (8.6)
adjuvant chemotherapy 10 (17.2)
Abbreviations: CT, chemotherapy; eCOg, eastern Cooperative Oncology group; 
FOLFIRI, folinic acid, fluorouracil and irinotecan; FOLFOX, folinic acid fluorouracil 
and oxaliplatin; Msi, microsatellite instability.
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levels and RAS and BRAF status (data not shown). Moreover, 
although there were no significant correlations between MSI 
status and serum protein levels (data not shown), a higher 
frequency of MSI tumors was observed in patients with low 
levels of IL-8 and Ang-2.
Objective response rate
There were a total of 38 patients responders and 20 nonre-
sponders. We observed a significant difference in median base-
line biomarker levels between responders and nonresponders, 
in particular for VEGF-C, MDC, and EGF (2,311 pg/mL 
[range 1,107–3468] vs 1,871 pg/mL [range 1,871–2,825] 
[P=0.001]; 645 pg/mL [range 161–1,154] vs 424 pg/mL 
[range 136–1,170] [P=0.033] and 196 pg/mL [range 49–511] 
vs 132 pg/mL [range 40–388] [P=0.018], respectively). 
Higher response rates were seen in patients with baseline 
VEGF-C, MDC, and EGF levels higher than the median 
value (adjusted odds ratio [OR]=13.05, 95% CI 2.73–62.22 
[P=0.001]; OR=3.63, 95% CI 1.08–13.33 [P=0.031]; and 
OR=4.68, 95% CI 1.24–17.66 [P=0.023], respectively) 
(Table 2). No significant differences were observed between 
other baseline biomarkers and ORR (data not shown).
PFs and Os
Baseline IL-8 levels were correlated with PFS and OS; in 
particular, patients with ≥145 pg/mL IL-8 showed a shorter 
median PFS and OS than those with lower levels (6.5 vs 12.6 
months, HR 7.39, 95% CI 2.76–19.83 [P<0.0001] and 8.7 
vs 28.8 months, HR 7.68, 95% CI 2.59–22.77 [P<0.001], 
respectively) (Figure 1 and Table 3). Moreover, patients with 
≥12,000 ng/mL TSP-1 levels showed a better median OS than 
those with lower levels (34.5 vs 13.1 months, HR 0.41, 95% 
CI 0.20–0.85 [P=0.016]) (Figure 1 and Table 3). Baseline 
Ang-2 levels showed borderline  significance with PFS and 
OS. Patients with ≥1,740 pg/mL Ang-2 levels showed a shorter 
median PFS and OS than those with lower levels (9.0 vs 12.5 
months, HR 1.99, 95% CI 0.89–4.45 [P=0.096] and 14.4 vs 
28.8 months, HR 2.56, 95% CI 1.07–6.12 [P=0.035], respec-
tively). No significant differences were observed between other 
biomarkers at baseline and PFS and OS (data not shown).
serum protein modulation during therapy
We analyzed the variation in serum proteins from baseline 
to the first clinical evaluation. With regard to ORR, it was 
seen that patients with ≥20% reduction in Ang-2 levels had 
a higher ORR than those with a lower reduction (adjusted 
OR=4.29, 95% CI 1.13–16.31, P=0.003). A borderline 
significance was also observed for IL-8 modulation; in par-
ticular, patients with ≥20% reduction in IL-8 levels showed a 
higher ORR than those showing a lower reduction (adjusted 
OR=2.89, 95% CI 0.91–9.2, P=0.073).
We also evaluated PFS and OS in relation to serum bio-
marker changes observed between baseline and the first clinical 
evaluation. Patients with a ≥20% reduction (N=36) in IL-8 
levels showed a better median PFS and OS than those with 
a <20% reduction (N=10) or an increase (N=9) (12.8 vs 9.1 
months, HR 0.41, 95% CI 0.22–0.77, P=0.005 and 31.7 vs 19.3 
months, HR 0.43, 95% CI 0.23–0.79, P=0.007, respectively). 
Figure 2 shows the Kaplan–Meier curves for PFS and OS with 
respect to the reduction in IL-8 level between baseline and the 
first clinical evaluation. Patients with a ≥20% reduction in IL-6 
levels had a better median PFS than those with <20% reduction 
or an increase (14.0 months, 95% CI 9.0–25.1 vs 10.1 months, 
95% CI 6.8–13.1, HR 0.56, 95% CI 0.32–0.99) (P=0.046). 
Moreover, patients with a ≥50% reduction in VEGF-C levels 
between baseline and the first clinical evaluation showed a 
Table 2 Correlation between serum proteins and overall response rate
Baseline serum protein  
levels (pg/mL)
CR/PR (N=38) SD/PD (N=20) OR (95% CI)a P-valuea
N (%) N (%)
VEGF-C
<2,128 13 (44.8) 16 (55.2) 1.00
≥2,128 25 (86.2) 4 (13.8) 13.05 (2.73–62.22) 0.001
MDC
<531 15 (51.7) 14 (48.3) 1.00
≥531 23 (79.3) 6 (20.7) 3.63 (1.08–13.33) 0.031
EGF
<179 15 (51.7) 14 (48.3) 1.00
≥179 23 (79.3) 6 (20.7) 4.68 (1.24–17.66) 0.023
Notes: aadjusted for chemotherapy regimen, gender, age, RAS status, and tumor localization.
Abbreviations: CR, complete response; egF, epidermal growth factor; MDC, macrophage-derived chemokine; PD, progressive disease; PR, partial response; sD, stable 
disease; VegF, vascular endothelial growth factor.
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shorter PFS compared with those with <50% reduction (6.9 
months, 95% CI 2.9–9.2 vs 12.5 months, 95% CI 9.6–14.9, HR 
3.99, 95% CI 0.32–0.99) (P=0.046). There was no significant 
difference between the modulation of other biomarkers and 
clinical outcome (data not shown).
Discussion
In the present study, we investigated the role of several 
angiogenesis-associated proteins and cytokines, evaluated 
Figure 1 Progression-free survival (PFs) and overall survival (Os) with respect to baseline il-8 (A and B, respectively) and TsP-1 levels (C and D, respectively).
Notes: aadjusted for chemotherapy regimen, gender, age, RAS status, and tumor localization.
Abbreviation: TsP-1, thrombospondin-1.
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Table 3 Progression-free and overall survival with respect to baseline serum protein levels
Baseline 
serum 
protein levels
No. of 
patients
No. of 
events
Median value 
(95% CI)
HRa (95% CI) P-valuea No. of 
events
Median value 
(95% CI)
HRa (95% CI) P-valuea
IL-8
<145 52 48 12.6 (9.6–15.4) 1.00 42 28.8 (21.4–36.7) 1.00
≥145 6 6 6.5 (1.9–9.7) 7.39 (2.76–19.83) <0.0001 5 8.7 (4.7–14.4) 7.68 (2.59–22.77) <0.001
TSP-1
<12,000 18 17 9.2 (5.0–12.2) 1.00 17 13.1 (9.0–22.7) 1.00
≥12,000 40 37 12.9 (9.6–15.9) 0.62 (0.32–1.20) 0.160 30 34.5 (21.0–44.4) 0.41 (0.20–0.85) 0.016
Notes: il-8 measured in pg/ml; TsP-1 measured in ng/ml; aadjusted for chemotherapy regimen, gender, age, RAS status, and tumor localization.
Abbreviation: TsP, thrombospondin.
at baseline and during B treatment, with respect to clinical 
outcome.
Our findings showed that low baseline IL-8 and high 
TSP-1 levels were associated with better clinical outcome, 
and that a >20% reduction in IL-8 levels between baseline 
and the first evaluation was associated with better PFS and 
OS. In agreement with our results, di Salvatore et al observed 
that B-treated mCRC patients with low rather than high IL-8 
levels had significantly longer median PFS and OS.15 Of note, 
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they also found that the IL-8 single-nucleotide polymorphism 
c.-251 “A” allele was associated with significantly shorter 
PFS and OS. Given that this allele would appear to be cor-
related with variations in promoter transcriptional activity 
and higher levels of circulating IL-8,16–18 their data support 
the hypothesis that patients carrying the A allele may benefit 
less from B because of higher IL-8 serum levels.
A number of authors have published similar results on 
the role of IL-8 in mCRC patients receiving B.5,8 Abajo et al 
reported a better clinical outcome when IL-8 baseline levels 
were lower,8 while Kopetz et al observed that elevated IL-8 
at baseline was associated with a shorter PFS.5 We found 
that lower baseline IL-8 serum levels were associated with 
better PFS and OS. IL-8 is believed to promote migration, 
invasion, and in vivo angiogenesis by stimulating endothelial 
cell proliferation in response to hypoxia,19–22 suggesting a 
possible role in tumor resistance.
With regard to TSP-1 in CRC, high tissue levels have been 
shown to correlate with higher survival rates.23 Moreover, 
Figure 2 Progression-free survival (PFs) (A) and overall survival (Os) (B) with respect to reduction in IL-8 levels observed between baseline and first clinical evaluation.
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Loupakis et al evaluated plasma levels of several angiogen-
esis-related proteins at different time points in a cohort of 25 
patients undergoing CT+ B, observing a significant increase 
in TSP-1 levels when the disease progressed.6 Within this 
context, Brostjan et al reported significant variations in TSP-1 
plasma levels after treatment with B.24 Our data demonstrated 
that patients with higher baseline VEGF-C, MDC, and EGF 
levels also had a better clinical outcome.
In agreement with our results, Abajo et al reported that high 
serum levels of EGF and MDC were associated with higher 
response rates. MDC attracts and activates a variety of cell 
types and enhance the immune response.25 Accordingly, high 
baseline levels of MDC in our responding patients would seem 
to suggest a role in promoting an immune response by T-helper 
cell recruitment. Moreover, patients in our study showing a 
reduction in IL-6 levels had better PFS. Similarly, Abajo et al 
observed lower IL-6 levels in patients responding to therapy.
The better outcome observed in the subset of patients 
with lower IL-6 and IL-8 levels is in agreement with the 
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role ascribed to these cytokines in colon cancer progression 
and angiogenesis.26,27 We also obtained interesting results 
for Ang-2; in particular, high baseline levels were associated 
with a poorer clinical outcome. Similar findings have been 
reported in the literature for other tumors, including CRC, 
treated with B-base therapy.28–32
We also assessed biomarker levels in relation to the main 
molecular features, RAS, BRAF, and MSI status, but no sig-
nificant correlations were observed. However, all MSI-high 
patients (12%) showed low levels of IL-8 and Ang-2 at base-
line. Pogue-Geile et al reported that CRC patients diagnosed 
with MSI-high tumors showed a significant survival benefit 
from the addition of bevacizumab compared with no benefit 
in patients without MSI.33 These results are in agreement with 
our own findings if we consider that lower levels of IL-6 and 
Ang2 were correlated with better survival.
Moreover, our previous study demonstrated a higher 
benefit from the addition of bevacizumab to CT in right-
sided tumors,34 in agreement with the CALGB/SWOG 80405 
trial.35 Venook et al showed that bevacizumab significantly 
improved survival parameters in patients with right-sided 
lesions, while treatment with cetuximab improved PFS and 
OS in those with left-sided KRAS wild-type disease.35 In this 
context, it would be interesting to study serum biomarkers of 
response to bevacizumab, as evaluated in our study.
A limitation of our study is that we did not analyze the 
control arm receiving CT only. Thus, a clear distinction could 
not be made between the prognostic and predictive role of 
the serum biomarkers in relation to survival. Moreover, given 
the exploratory nature of the study, adjustments for multiple 
comparisons were not made. Overall, although our study is 
somewhat limited by its small sample size, the results were 
obtained on a (prospectively enrolled) patient population 
treated homogeneously in a randomized, prospective Phase III 
multicenter study (ITACa trial).14 An independent prospective 
study is ongoing to validate our results.
Conclusion
Our results suggest that low baseline IL-8 levels and their 
reduction during B treatment and high baseline levels of 
TSP-1 may indicate better clinical outcome in mCRC patients 
treated with B. Our data, if confirmed in larger independent 
studies, would suggest a role of these angiogenic proteins in 
determining B efficacy.
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